Trials / Completed
CompletedNCT03829241
Randomized Trial of Adult Participants With Generalized Anxiety Disorder
A Multicenter, Randomized, Double-Blind, Placebo Controlled Trial of Troriluzole in Generalized Anxiety Disorder
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 881 (actual)
- Sponsor
- Biohaven Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the efficacy of troriluzole versus placebo in participants with generalized anxiety disorder.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Troriluzole | 100 mg capsule |
| DRUG | Placebo | Placebo matched to troriluzole |
Timeline
- Start date
- 2019-02-19
- Primary completion
- 2020-01-14
- Completion
- 2020-05-08
- First posted
- 2019-02-04
- Last updated
- 2024-05-08
- Results posted
- 2022-12-28
Locations
53 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03829241. Inclusion in this directory is not an endorsement.